GSK to Invest $800M+ in Pennsylvania Expansion

Editor’s Take: Pennsylvania’s life sciences industry is home to approximately 3,900 companies, employs more than 110,000 Pennsylvanians, and directly contributes $73 billion to the economy.

Pennsylvania has secured an over $800 million investment from global biopharma company GSK to expand its operations in Montgomery County.

GSK is expanding its facilities in Upper Merion Township, with construction planned to begin in 2027. The expansion will establish a biopharmaceutical innovation and manufacturing hub, integrating commercial production, research and development, and advanced digital capabilities in a single site.

The expansion will also create more than 300 new jobs over the next five years, retain approximately 4,500 existing full-time jobs across the state, and continue growing Pennsylvania’s life sciences industry.

This announcement marks GSK’s second major expansion in Pennsylvania since Governor Josh Shapiro took office, previously investing $800 million in Lancaster County — a total of nearly $1.7 billion in the state.

“Investing in additional commercial and R&D manufacturing with advanced digital capabilities at our Upper Merion site will help accelerate the development and supply of future medicines for patients,” said Regis Simard, President, GSK Global Supply Chain. “The Commonwealth of Pennsylvania has been an important partner in supporting GSK’s growth, innovation, and manufacturing footprint in the United States. By expanding in Upper Merion, we’re building on that longstanding partnership while creating high-quality jobs and strengthening our ability to deliver the next generation of medicines.”

The expansion project will include the demolition of existing buildings and construction of new and enhanced facilities including a commercial-scale biologics manufacturing facility capable of supporting both clinical and commercial supply, a co-located research and development pilot plant to accelerate tech transfer and process development, and a centralized quality control lab and manufacturing science & technology (MSAT) hub.

The company will be eligible for tax benefits through the Qualified Manufacturing Innovation and Reinvestment Deduction (QMIRD) program and the Manufacturing Tax Credit (MTC) program.

Other Pennsylvania Investments

Lilly recently chose the Lehigh Valley in Pennsylvania for its next manufacturing site.

Altasciences recently expanded the R&D laboratory at its Harleysville, PA drug product formulation and manufacturing services facility.